Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 13/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20100691 | 0.82 | CHRM1 (0.43) | CHRM1 | |
| SCHEMBL20100688 | 0.79 | CHRM1 (0.40) | CHRM1GRM5GRM1 | |
| SCHEMBL20100687 | 0.75 | CHRM1 (0.34) | CHRM1 | |
| SCHEMBL20100690 | 0.75 | CHRM1 (0.33) | CHRM1 | |
| SCHEMBL20100693 | 0.74 | CHRM1 (0.54) | CHRM1 | |
| SCHEMBL20100689 | 0.73 | CHRM1 (0.56) | CHRM1 | |
| SCHEMBL20100685 | 0.73 | CHRM1 (0.38) | CHRM1 | |
| SCHEMBL20100695 | 0.71 | CHRM1 (0.65) | CHRM1 | |
| SCHEMBL20100696 | 0.71 | CHRM1 (0.55) | CHRM1 | |
| SCHEMBL20100692 | 0.66 | CHRM1 (0.36) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118746-A1 | SUBSTITUTED IMIDAZOPYRIDINE AND TRIAZOLOPYRIDINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118746-A1 | SUBSTITUTED IMIDAZOPYRIDINE AND TRIAZOLOPYRIDINE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM5, CHRM4 | CHRM1 1/4885SMN1; SMN2 2138/4885PBRM1 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.